These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 37437090)

  • 21. Zoledronic acid in osteoporosis secondary to mastocytosis.
    Rossini M; Zanotti R; Viapiana O; Tripi G; Idolazzi L; Biondan M; Orsolini G; Bonadonna P; Adami S; Gatti D
    Am J Med; 2014 Nov; 127(11):1127.e1-1127.e4. PubMed ID: 24954632
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Zoledronic acid versus alendronate for the prevention of bone loss after heart or liver transplantation.
    Shane E; Cohen A; Stein EM; McMahon DJ; Zhang C; Young P; Pandit K; Staron RB; Verna EC; Brown R; Restaino S; Mancini D
    J Clin Endocrinol Metab; 2012 Dec; 97(12):4481-90. PubMed ID: 23024190
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effect of once-yearly zoledronic acid on hip structural and biomechanical properties derived using computed tomography (CT) in Japanese women with osteoporosis.
    Ito M; Sone T; Shiraki M; Tanaka S; Irie C; Ota Y; Nakamura T
    Bone; 2018 Jan; 106():179-186. PubMed ID: 29033381
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia intermedia-induced osteoporosis.
    Voskaridou E; Christoulas D; Antoniadou L; Terpos E
    Acta Haematol; 2008; 119(1):40-4. PubMed ID: 18253025
    [No Abstract]   [Full Text] [Related]  

  • 25. Zoledronate once-yearly increases bone mineral density--implications for osteoporosis.
    Doggrell SA
    Expert Opin Pharmacother; 2002 Jul; 3(7):1007-9. PubMed ID: 12083999
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of zoledronic acid on bone mineral density around prostheses and bone metabolism markers after primary total hip arthroplasty in females with postmenopausal osteoporosis.
    Zhou W; Liu Y; Guo X; Yang H; Xu Y; Geng D
    Osteoporos Int; 2019 Aug; 30(8):1581-1589. PubMed ID: 31115592
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of zoledronic acid on bone mineral density in premenopausal women receiving neoadjuvant or adjuvant therapies for HR+ breast cancer: the ProBONE II study.
    Hadji P; Kauka A; Ziller M; Birkholz K; Baier M; Muth M; Bauer M
    Osteoporos Int; 2014 Apr; 25(4):1369-78. PubMed ID: 24504100
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Modeling and simulation of bone mineral density in Japanese osteoporosis patients treated with zoledronic acid using tartrate-resistant acid phosphatase 5b, a bone resorption marker.
    Mori Y; Kasai H; Ose A; Serada M; Ishiguro M; Shiraki M; Tanigawara Y
    Osteoporos Int; 2018 May; 29(5):1155-1163. PubMed ID: 29423715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment for osteoporosis in people with ß-thalassaemia.
    Bhardwaj A; Swe KM; Sinha NK; Osunkwo I
    Cochrane Database Syst Rev; 2016 Mar; 3():CD010429. PubMed ID: 26964506
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone health in cerebral palsy and introduction of a novel therapy.
    Scheinberg MA; Golmia RP; Sallum AM; Pippa MG; Cortada AP; Silva TG
    Einstein (Sao Paulo); 2015; 13(4):555-9. PubMed ID: 26761553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomized controlled trial of zoledronic acid for treatment of osteoporosis in women.
    Bai H; Jing D; Guo A; Yin S
    J Int Med Res; 2013 Jun; 41(3):697-704. PubMed ID: 23669294
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bisphosphonate treatment for children with disabling conditions.
    Boyce AM; Tosi LL; Paul SM
    PM R; 2014 May; 6(5):427-36. PubMed ID: 24368091
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pamidronate treatment and posttreatment bone density in children with spastic quadriplegic cerebral palsy.
    Bachrach SJ; Kecskemethy HH; Harcke HT; Lark RK; Miller F; Henderson RC
    J Clin Densitom; 2006; 9(2):167-74. PubMed ID: 16785077
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial.
    Westin JR; Thompson MA; Cataldo VD; Fayad LE; Fowler N; Fanale MA; Neelapu S; Samaniego F; Romaguera J; Shah J; McLaughlin P; Pro B; Kwak LW; Sanjorjo P; Murphy WA; Jimenez C; Toth B; Dong W; Hagemeister FB
    Clin Lymphoma Myeloma Leuk; 2013 Apr; 13(2):99-105. PubMed ID: 23276888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Role of zoledronic acid in the prevention and treatment of osteoporosis.
    Räkel A; Boucher A; Ste-Marie LG
    Clin Interv Aging; 2011; 6():89-99. PubMed ID: 21594000
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Zoledronic acid prevents bone loss after liver transplantation: a randomized, double-blind, placebo-controlled trial.
    Crawford BA; Kam C; Pavlovic J; Byth K; Handelsman DJ; Angus PW; McCaughan GW
    Ann Intern Med; 2006 Feb; 144(4):239-48. PubMed ID: 16490909
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial.
    Yang L; Sycheva AV; Black DM; Eastell R
    Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acute and long-term effects of zoledronate in adult patients with osteogenesis imperfecta. An observational Spanish study with five years of follow-up.
    Pavón de Paz I; Rosado Sierra JA; Pérez Blanco C; Modroño Móstoles N; Guijarro de Armas G; Navea Aguilera C
    Endocrinol Diabetes Nutr (Engl Ed); 2019 Feb; 66(2):108-116. PubMed ID: 30077631
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravenous zoledronic acid for the treatment of osteoporosis.
    Lewiecki EM
    Curr Osteoporos Rep; 2008 Mar; 6(1):17-23. PubMed ID: 18430396
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials.
    Wang C
    Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.